Astragalin, a natural flavonoid glycoside found in various medicinal plants such as Polygonum aviculare and Astragalus membranaceus, has been investigated in recent years for its potential effects on bone health and osteoporosis. Preclinical studies, primarily in vitro and in animal models, provide some scientific rationale for its use in supporting bone density and inhibiting bone loss. For instance, a 2019 study by Zhang et al. (Frontiers in Pharmacology) demonstrated that astragalin could suppress osteoclast differentiation and function by inhibiting the NF-κB and MAPK signaling pathways, key regulators in bone resorption processes. Other research has indicated that astragalin may possess antioxidant and anti-inflammatory properties, which could help modulate the bone microenvironment and slow the progression of osteoporosis.

However, it is important to note that most of the evidence comes from laboratory or animal studies, and there is a lack of high-quality clinical trials in humans to substantiate its efficacy and safety for osteoporosis treatment or prevention. There is also limited evidence of traditional use of astragalin specifically for osteoporosis, though plants containing astragalin are used in traditional medicine for general bone health. As such, while there is emerging scientific validation at the experimental level, the evidence is currently limited (rated 2/5) and does not yet support routine clinical use in humans.